Survivors of childhood cancer are at risk for premature chronic renal failure as their glomerular function continues to deteriorate, according to a study of 1,122 childhood-cancer survivors aged 18 years and older.
After a median follow-up of 21 years after cancer diagnosis, glomerular function deteriorated over time in all subjects, particularly those treated with higher doses of cisplatin, researchers reported in Cancer Epidemiology, Biomarkers & Prevention (2013;22:1736-1746).
Cisplatin, ifosfamide, and nephrectomy were associated with worse glomerular function that persisted during the entire follow-up period. Survivors treated with potentially nephrotoxic medications had a significantly lower glomerular filration rate and higher glomerular dysfunction probability up to 35 years after cancer diagnosis compared with survivors who did not undergo nephrotoxic therapy.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.